Balaxi Pharmaceuticals Reports Strong Q2 Results, Secures WHO-GMP Certification, and Announces Leadership
Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:33 pm
Balaxi Pharmaceuticals Reports Strong Q2 Results, Secures WHO-GMP Certification, and Announces Leadership Update Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for Q2 ended 30th Sep'26, up 44.85% YoY from ₹5,617.53 lakhs. Net profit rose to ₹115.02 lakhs from ₹20.90 lakhs YoY. The company received WHO-GMP certification from CDSCO for its Jadcherla formulation facility, where commercial production is scaling up for Angola and Dominican Republic markets with 22 products manufactured and approvals reaching 34 products. Additionally, Pranav Maheshwari was redesignated as President – Business and Corporate Strategy, effective 12th Nov'26.
Original exchange filing (PDF)
More announcements from Balaxi Pharmaceuticals Ltd
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation · 16 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding a press release dated November 12, 2026, titled "Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY". · 13 Nov 2026
- Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on November 12, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026". · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. · 12 Nov 2026
